Navigation Links
Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
Date:7/28/2010

VANCOUVER, July 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, which represent at least four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

The phase I clinical trial is an open label, multi-center dose escalation trial evaluating the safety and maximum tolerated dose of a single administration of allogeneic MultiStem cells following an AMI. Enrolled patients received MultiStem delivered via a catheter into the damaged region of the heart 2-5 days following percutaneous coronary intervention (PCI), a standard treatment for heart attack. The study includes patients in three treatment cohorts or dose groups (20 million, 50 million and 100 million cells per patient) and a registry group where patients received only standard of care. Nineteen treated and six registry subjects participated in the study. The trial is being conducted at cardiovascular treatment centers in the United States, including the Cleveland Clinic, Columbia University Medical Center and Henry Ford Health System.

Highlights of the Study:

    -   Administration of MultiStem was found to be well tolerated at all
        dose levels
    -   No clinically significant changes in vital signs, allergic reactions,
        or infusion-related toxicities were associated with MultiStem
        administration
    -   Each dose group showed
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
3. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
4. Angiotech Pharmaceuticals Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
8. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
10. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... InferMed , s decision ... augment Elsevier ... suite   Elsevier , a world-leading provider ... today the acquisition of  InferMed , a London ... InferMed,s Arezzo technology supports clinicians in choosing the most appropriate ...
(Date:7/1/2015)... ... 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks can ... Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original Equipment ... increase healthcare worker safety and reduce financial costs. , CTI Electronics announces a ...
(Date:6/30/2015)... , July 1, 2015 R-Japan Co.,Ltd. obtained ... the Safety of Regenerative Medicine from the Ministry of Health, ... June 29, 2015. The fact that R- ... facility through the auditing from Pharmaceuticals and Medical Devices Agency ... application, allows it to provide stem cell manufacturing service to ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) ... of Resverlogix have approved the resolutions relating to: ... of 5,600,000 units at a price of $2.67 ... being comprised of one common share and 0.075358 ... approximately CAD$15 million; and (ii) the amendment to ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... , KENILWORTH, N.J., Aug. 26 Schering-Plough ... European Medicines Agency (EMEA) has validated (accepted for review) the ... mometasone furoate and formoterol fumarate for the maintenance treatment of ... The company also announced today that the EMEA has validated ...
... N.C., Aug. 26 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... New York on Sept. 9 and Zurich on Sept. 10, 2009. ... Division and Government Affairs, will present at the Rodman & Renshaw ... at 2:00 p.m. eastern time. , , A ...
... , ... Trusted LASIK Surgeons launched its revolutionary Trusted LASIK Surgeons directory service and website ... to improve their vision and find a highly qualified eye surgeon who can ... apart is a unique screening process ensuring that only those who are among ...
Cached Biology Technology:Schering-Plough Announces Two European Filings 2Schering-Plough Announces Two European Filings 3Schering-Plough Announces Two European Filings 4Schering-Plough Announces Two European Filings 5Schering-Plough Announces Two European Filings 6Schering-Plough Announces Two European Filings 7Schering-Plough Announces Two European Filings 8Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich 2LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 2LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 3LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 4LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 5LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 6LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 7
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards has ... sensors in the company,s portfolio from one of its module ... to mainly take place during the third quarter 2015. The ... Asia . Jörgen Lantto, CEO of FPC, ... the   growing interest from smartphone OEMs in integrating touch ...
(Date:6/15/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces that its leading payment security technology, the ... Experience! @ NYC June 18th. Digital Experience! @ ... in technology to over 300 of the top media covering ... Pavilion in New York City from ...
(Date:6/9/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, will be providing demonstrations of its ... Drug Information Association (DIA) Annual Meeting in ... will include previews of many exciting new enhancements that ... iMedNet 2015 Feature 1 Release. ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... Researchers have teased out the molecular process that can ... kills thousands each year who suffer battlefield casualties, heart ... an article published in the January edition of ... the enormously complex biomechanics of a reaction first observed ...
... The National Institute of Allergies and Infectious Diseases (NIAID), ... awarded a five-year contract totaling $15,254,919 to Tulane University ... fever, an often deadly viral disease that threatens hundreds ... is classified as a potential bioterrorism threat. The ...
... Iowa -- A previous six-month study by Iowa State ... soy protein, rich in isoflavones, lessened lumbar spine bone ... three-year study by some of those same researchers does ... ingested soy isoflavone tablets, except for a modest effect ...
Cached Biology News:Research could lead to way to halt deadly immune response 2Research could lead to way to halt deadly immune response 3Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 2Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 3
... Mass Spectrometry Applications ,In the age ... emerged as a powerful protein identification and ... is now an important intermediate step in ... to identification of specific proteins in the ...
... the only PCR system that ensures successful ... It provides accuracy, consistency, and dependability for ... property of the DNA templates. This system ... unique blend of thermostable enzymes that is ...
... Application: A cleaning agent ... plastic surfaces, countertops, and pipettors. ... at eliminating RNase contamination from ... enzymatic reactions. ,RNase Zap ...
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: